Free Trial

ASGN (NYSE:ASGN) Releases Earnings Results, Beats Expectations By $0.09 EPS

ASGN logo with Computer and Technology background

ASGN (NYSE:ASGN - Get Free Report) issued its quarterly earnings data on Wednesday. The business services provider reported $1.17 earnings per share for the quarter, beating analysts' consensus estimates of $1.08 by $0.09, Zacks reports. ASGN had a return on equity of 11.98% and a net margin of 3.50%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $994.64 million. During the same quarter last year, the firm earned $1.36 EPS. ASGN's quarterly revenue was down 1.4% on a year-over-year basis. ASGN updated its Q3 2025 guidance to 1.180-1.260 EPS.

ASGN Stock Performance

NYSE:ASGN traded down $0.95 during midday trading on Friday, reaching $54.70. 1,297,504 shares of the company traded hands, compared to its average volume of 527,968. ASGN has a twelve month low of $46.63 and a twelve month high of $101.66. The firm has a market capitalization of $2.40 billion, a price-to-earnings ratio of 17.31 and a beta of 0.97. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.37 and a quick ratio of 2.37. The company has a fifty day moving average price of $51.68 and a 200 day moving average price of $63.37.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Wells Fargo & Company decreased their target price on ASGN from $56.00 to $51.00 and set an "equal weight" rating for the company in a research report on Thursday. Truist Financial decreased their target price on ASGN from $105.00 to $75.00 and set a "buy" rating for the company in a research report on Tuesday, April 15th. Jefferies Financial Group reiterated an "underperform" rating and issued a $42.00 target price (down previously from $53.00) on shares of ASGN in a research report on Monday, July 7th. Canaccord Genuity Group reiterated a "hold" rating and issued a $55.00 target price (down previously from $115.00) on shares of ASGN in a research report on Friday, April 25th. Finally, UBS Group reduced their price objective on ASGN from $49.00 to $47.00 and set a "sell" rating for the company in a research report on Thursday. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $61.67.

Get Our Latest Research Report on ASGN

ASGN Company Profile

(Get Free Report)

ASGN Incorporated engages in the provision of information technology (IT) services and solutions in the technology, digital, and creative fields for commercial and government sectors in the United States, Canada, and Europe. It operates through two segments: Commercial and Federal Government. The Commercial Segment provides consulting, creative digital marketing, and permanent placement services primarily to enterprise clients.

Further Reading

Earnings History for ASGN (NYSE:ASGN)

Should You Invest $1,000 in ASGN Right Now?

Before you consider ASGN, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ASGN wasn't on the list.

While ASGN currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines